Dataset Information


Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trial.

ABSTRACT: Ankylosing spondylitis (AS) is a chronic inflammatory autoimmune disease. Kunxian capsule, a Chinese patent medicine which has been used in the treatment of immunologic diseases for many years in China, has anti-inflammatory and immunoregulatory effects. This study investigates the efficacy and safety of Kunxian capsules in the treatment of AS.This was a randomized, double-blind, parallel control clinical trial involving 80 patients with AS who fulfilled the modified New York criteria (1984) and had active disease defined by a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ?40 mm under background stable nonsteroidal anti-inflammatory drugs (NSAIDs) for more than 4 weeks. Patients were randomly divided into two groups, the Kunxian group and the placebo group, and Kunxian (0.6 g, three times per day) and the placebo were provided for 12 weeks. The primary endpoint was the Assessment of SpondyloArthritis international Society (ASAS) 20 response rate at week 12. The secondary endpoints were ASAS 40, BASDAI 50, the Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI), and Ankylosing Spondylitis Disease Activity Score on the basis of C-reactive protein level (ASDAS-CRP) at weeks 2, 6, and 12.The primary endpoint of ASAS 20 at week 12 was achieved in 13 of 35 patients (37.1 %) among the Kunxian group, compared with 4 of 33 (12.1 %) in the placebo group (p?


PROVIDER: S-EPMC4957347 | BioStudies | 2016-01-01

REPOSITORIES: biostudies

Similar Datasets

2013-01-01 | S-EPMC3664374 | BioStudies
2012-01-01 | S-EPMC3329233 | BioStudies
2015-01-01 | S-EPMC4365732 | BioStudies
2016-01-01 | S-EPMC5192572 | BioStudies
2020-01-01 | S-EPMC6942415 | BioStudies
2014-01-01 | S-EPMC4282738 | BioStudies
2015-01-01 | S-EPMC4755041 | BioStudies
2014-01-01 | S-EPMC4448884 | BioStudies
2014-01-01 | S-EPMC3888598 | BioStudies
2016-01-01 | S-EPMC5132041 | BioStudies